Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Intra-Cellular price target raised to $93 from $90 at Canaccord » 07:57
11/04/22
11/04
07:57
11/04/22
07:57
ITCI

Intra-Cellular

$51.79 /

+5.87 (+12.78%)

Canaccord analyst Sumant…

Canaccord analyst Sumant Kulkarni raised the firm's price target on Intra-Cellular to $93 from $90 and keeps a Buy rating on the shares. The analyst said the shares are still significantly undervalued on currently approved indications while the robust Caplyta performance reinforces the stock's potential.

ShowHide Related Items >><<
ITCI Intra-Cellular
$51.79 /

+5.87 (+12.78%)

ITCI Intra-Cellular
$51.79 /

+5.87 (+12.78%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$51.79 /

+5.87 (+12.78%)

  • 05
    Jan
Over a month ago
Earnings
Intra-Cellular reports Q3 EPS (57c), consensus (81c) » 07:34
11/03/22
11/03
07:34
11/03/22
07:34
ITCI

Intra-Cellular

$45.84 /

-0.14 (-0.30%)

Reports Q3 revenues…

Reports Q3 revenues $71.9M, consensus $66M. "The successful launch of CAPLYTA continues with another quarter of strong revenue growth. In addition to our efforts to fuel continued commercial success, we are making investments to broaden CAPLYTA's indications and advance our pipeline," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

ShowHide Related Items >><<
ITCI Intra-Cellular
$45.84 /

-0.14 (-0.30%)

ITCI Intra-Cellular
$45.84 /

-0.14 (-0.30%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$45.84 /

-0.14 (-0.30%)

  • 05
    Jan
Conference/Events
Intra-Cellular to participate in a conference call with Cantor Fitzgerald » 13:25
10/04/22
10/04
13:25
10/04/22
13:25
ITCI

Intra-Cellular

$48.20 /

+0.45 (+0.94%)

Conference call with…

Conference call with management will be held on October 4 at 2 pm hosted by Cantor Fitzgerald. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$48.20 /

+0.45 (+0.94%)

ITCI Intra-Cellular
$48.20 /

+0.45 (+0.94%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$48.20 /

+0.45 (+0.94%)

  • 05
    Jan
Conference/Events
Intra-Cellular to participate in a conference call with Cantor Fitzgerald » 04:55
10/04/22
10/04
04:55
10/04/22
04:55
ITCI

Intra-Cellular

$47.75 /

+1.185 (+2.55%)

Conference call with…

Conference call with management will be held on October 4 at 2 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
ITCI Intra-Cellular
$47.75 /

+1.185 (+2.55%)

ITCI Intra-Cellular
$47.75 /

+1.185 (+2.55%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$47.75 /

+1.185 (+2.55%)

  • 05
    Jan
Conference/Events
Intra-Cellular to participate in a conference call with Cantor Fitzgerald » 17:30
09/27/22
09/27
17:30
09/27/22
17:30
ITCI

Intra-Cellular

$44.60 /

+1.8 (+4.21%)

Conference call with…

Conference call with management will be held on October 4 at 2 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
ITCI Intra-Cellular
$44.60 /

+1.8 (+4.21%)

ITCI Intra-Cellular
$44.60 /

+1.8 (+4.21%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$44.60 /

+1.8 (+4.21%)

  • 05
    Jan
Conference/Events
Intra-Cellular participates in a conference call with JPMorgan » 13:50
09/07/22
09/07
13:50
09/07/22
13:50
ITCI

Intra-Cellular

$50.71 /

-0.08 (-0.16%)

Conference call with…

Conference call with Chairman & CEO Mates, CFO Hineline and CCO Neumann will be held on September 7 at 2 pm hosted by JPMorgan. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$50.71 /

-0.08 (-0.16%)

ITCI Intra-Cellular
$50.71 /

-0.08 (-0.16%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$50.71 /

-0.08 (-0.16%)

  • 05
    Jan
Conference/Events
Intra-Cellular participates in a conference call with JPMorgan » 11:19
09/07/22
09/07
11:19
09/07/22
11:19
ITCI

Intra-Cellular

$51.07 /

+0.28 (+0.55%)

Conference call with…

Conference call with Chairman & CEO Mates, CFO Hineline and CCO Neumann will be held on September 7 at 2 pm hosted by JPMorgan. Webcast Link

ShowHide Related Items >><<
ITCI Intra-Cellular
$51.07 /

+0.28 (+0.55%)

ITCI Intra-Cellular
$51.07 /

+0.28 (+0.55%)

08/22/22 Goldman Sachs
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
ITCI Intra-Cellular
$51.07 /

+0.28 (+0.55%)

  • 05
    Jan
Over a quarter ago
Downgrade
Intra-Cellular downgraded to Neutral from Buy at Goldman Sachs » 04:38
08/22/22
08/22
04:38
08/22/22
04:38
ITCI

Intra-Cellular

$51.40 /

+0.64 (+1.26%)

Goldman Sachs analyst…

Goldman Sachs analyst Corinne Jenkins downgraded Intra-Cellular Therapies to Neutral from Buy with a price target of $49, down from $64. The stock has outperformed year-to-date, supported by a strong initial launch of Caplyta in bipolar depression, but there are early indicators that Caplyta prescription volume growth is slowing, Jenkins tells investors in a research note. The analyst also anticipates the entrance of generic Latuda to shift market dynamics in bipolar I disorder, which she believes "poses an incremental competitive threat" to Caplyta.

ShowHide Related Items >><<
ITCI Intra-Cellular
$51.40 /

+0.64 (+1.26%)

ITCI Intra-Cellular
$51.40 /

+0.64 (+1.26%)

07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
04/22/22 Piper Sandler
Intra-Cellular initiated with a Neutral at Piper Sandler
ITCI Intra-Cellular
$51.40 /

+0.64 (+1.26%)

  • 05
    Jan
Hot Stocks
Intra-Cellular director Marcus sells 10,000 common shares » 18:07
08/12/22
08/12
18:07
08/12/22
18:07
ITCI

Intra-Cellular

$53.57 /

-3.55 (-6.21%)

In a regulatory filing,…

In a regulatory filing, Intra-Cellular director Joel Marcus disclosed the sale of 10,000 common shares of the company on August 11 at a price of $59.22 per share.

ShowHide Related Items >><<
ITCI Intra-Cellular
$53.57 /

-3.55 (-6.21%)

ITCI Intra-Cellular
$53.57 /

-3.55 (-6.21%)

07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
04/22/22 Piper Sandler
Intra-Cellular initiated with a Neutral at Piper Sandler
ITCI Intra-Cellular
$53.57 /

-3.55 (-6.21%)

  • 05
    Jan
ITCI Intra-Cellular
$53.57 /

-3.55 (-6.21%)

Earnings
Intra-Cellular reports Q2 EPS (92c), consensus (76c) » 07:36
08/09/22
08/09
07:36
08/09/22
07:36
ITCI

Intra-Cellular

$58.87 /

-1.08 (-1.80%)

Reports Q2 revenue…

Reports Q2 revenue $55.6M, consensus $49.02M. "In this quarter, CAPLYTA experienced significant revenue growth, increasing nearly 60% over the first quarter of 2022, driven by strong uptake in bipolar depression. We expect to continue to deliver strong revenue growth throughout 2022 and also look forward to advancing our development programs," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

ShowHide Related Items >><<
ITCI Intra-Cellular
$58.87 /

-1.08 (-1.80%)

ITCI Intra-Cellular
$58.87 /

-1.08 (-1.80%)

07/06/22 Mizuho
Intra-Cellular initiated with a Buy at Mizuho
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
06/13/22 UBS
Intra-Cellular initiated with a Buy at UBS
04/22/22 Piper Sandler
Intra-Cellular initiated with a Neutral at Piper Sandler
ITCI Intra-Cellular
$58.87 /

-1.08 (-1.80%)

  • 05
    Jan
ITCI Intra-Cellular
$58.87 /

-1.08 (-1.80%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.